{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["231(1)"],"submitter":["Ananworanich J"],"funding":["Moderna, Inc"],"pubmed_abstract":["Background
Seasonal influenza remains a global public health concern. A messenger RNA (mRNA)-based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in a first-in-human, phase 1/2 clinical trial conducted in 3 parts.Methods
In parts 1 to 3 of this stratified observer-blind study, adults aged ≥18 years were randomly assigned to receive a single dose (6.25-200 µg) of mRNA-1010 or placebo (part 1) or an active comparator (Afluria; parts 2 and 3). Primary study objectives were assessment of safety, reactogenicity, and humoral immunogenicity of mRNA-1010, placebo (part 1), or active comparator (parts 2 and 3). Exploratory end points included assessment of cellular immunogenicity (part 1) and antigenic breadth against vaccine heterologous strains (A/H3N2; parts"],"journal":["The Journal of infectious diseases"],"pagination":["e113-e122"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11793046"],"repository":["biostudies-literature"],"pubmed_title":["Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial."],"pmcid":["PMC11793046"],"pubmed_authors":["Choi A","Carmona L","Kuo HH","Ananworanich J","Henry C","Avanesov A","Nachbagauer R","Paris R","Stadlbauer D","Lee IT","Schaefers K","Ensz D","Huang W","Chen R","Pucci A","McGrath S"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.","description":"Background
Seasonal influenza remains a global public health concern. A messenger RNA (mRNA)-based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in a first-in-human, phase 1/2 clinical trial conducted in 3 parts.Methods
In parts 1 to 3 of this stratified observer-blind study, adults aged ≥18 years were randomly assigned to receive a single dose (6.25-200 µg) of mRNA-1010 or placebo (part 1) or an active comparator (Afluria; parts 2 and 3). Primary study objectives were assessment of safety, reactogenicity, and humoral immunogenicity of mRNA-1010, placebo (part 1), or active comparator (parts 2 and 3). Exploratory end points included assessment of cellular immunogenicity (part 1) and antigenic breadth against vaccine heterologous strains (A/H3N2; parts","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-01T10:32:01.461Z","creation":"2026-04-08T11:32:00.277Z"},"accession":"S-EPMC11793046","cross_references":{"pubmed":["38934845"],"doi":["10.1093/infdis/jiae329"]}}